Cretap 10 mg (Rosuvastatin Calcium)
Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Genewon Science Co., Ltd.
MFDS item code 202001671 · Approved 2020.03.11
This product's status changed to Approval withdrawn on 2024.12.05. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
This medication is primarily used as an adjunct in patients with hypercholesterolemia and mixed hyperlipidemia when diet and exercise alone are not sufficient. It also helps lower LDL cholesterol levels in patients with familial hypercholesterolemia and slows the progression of atherosclerosis. It may be used as an adjunct to diet for pediatric patients aged 10 to 17 years who meet specific criteria. It helps patients with primary dysbetalipoproteinemia and is effective in reducing cardiovascular risk. This improves health by reducing the risk of stroke, myocardial infarction, and arterial revascularization.
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medication, and continue it throughout the treatment period. This medication may be taken at any time of day, regardless of meals. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams per day. 3. Older adults: No dose adjustment is required. 4. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering this medication at 20 mg to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. 6. Race: Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Ages 10 to 17 years: The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be individually adjusted according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy in children have not been established.
This drug should not be administered to certain patients. For example, patients with allergies to any ingredient of this drug, those with liver dysfunction, individuals with muscular diseases, patients taking certain medications in combination, and those with severe kidney dysfunction, pregnant or lactating women. Additionally, this drug should be used with caution in patients with liver dysfunction or those consuming large amounts of alcohol, and repeated liver function tests before and during treatment are recommended. If symptoms such as muscle pain or weakness occur, healthcare professionals should be notified immediately, and in severe cases, administration should be stopped. Rarely, this drug may cause serious skin reactions or liver damage, and muscle-related adverse effects, so if these symptoms appear, treatment should be stopped immediately and healthcare professionals should be consulted. Moreover, there may be drug interactions with other medications, so if you are taking other drugs, you must inform your healthcare provider, especially with certain antiviral agents, immunosuppressants, and fibrate drugs. Women who are pregnant or of childbearing potential should use appropriate contraception and discontinue use immediately if pregnancy is confirmed. It is also recommended that breastfeeding women avoid this medication. In the case of overdose, there are no specific antidotes, so management should involve treatment for symptoms along with monitoring liver function and muscle enzyme levels. This drug may cause dizziness, so caution is required when driving or operating machinery. Finally, this drug contains lactose, so patients with lactose intolerance should not take it. Additionally, Asian patients may exhibit higher drug concentrations; thus dose adjustment may be necessary.
Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, oculomotor weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), drug-induced erythrodermic eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paresthesia, chest discomfort, anorexia, abdominal distension, syncope, generalized pain, fatigue
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a tightly closed container. The suitable storage temperature is between 1 and 30 degrees Celsius at room temperature, and it is advisable to avoid very hot or very cold places.
Pink round film-coated tablet
28 tablets (14 tablets/PTP packaging x 2), 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Genewon Science Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Chong Kun Dang Pharmaceutical Corp.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Boryung Pharmaceutical Co., Ltd.

Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication
Jongkundang Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.